A Phase 3 interventional study of Pirtobrutinib and Idelalisib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Loxo Oncology, Inc.. Active, not recruiting at 232 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 9th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, reaches primary completion later than 0 of the 18 other live ones, and was the 2nd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Nurix Therapeutics, Inc. · Sites in United States
Ages 18+
Jennifer Woyach · Sites in United States
Ages 75+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 6 · Phase 4 3
First in 2019; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 238 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 87 across the 23 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Loxo Oncology, Inc., one of the names counted as Eli Lilly and Company. Under that name alone:
Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company: 5 open now, 9 under way, 4 of them phase 3. Of 3 finished, 1 (33%) have results posted.
Among the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2021, is one of 4 in phase 3, and was the 2nd registered.
Eli Lilly and Company’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2019.
3 of the studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06466122Kerry RogersPirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | 2026-12-31 |
| NCT06333262Inhye AhnFixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Eli Lilly and Company’s 13 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
This is a Phase 3 global, randomized, open-label study comparing LOXO-305 (Arm A) to investigator's choice of either idelalisib plus rituximab or bendamustine plus rituximab (Arm B) in CLL/SLL patients who have been treated with at least a covalent BTK inhibitor (BTKi). Patients may have discontinued the prior covalent BTKi due to disease progression (PD) or intolerance. Patients who have received venetoclax are eligible for the study. Eligible patients will be randomized in 1:1 to Arm A or Arm B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with the following :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 milligrams (mg) of pirtobrutinib administered orally once daily (QD) on Days 1 through 28 of a 28-day cycle. The treatment was continued until progressive disease, a discontinuation criterion, or unacceptable toxicity.
Drug: Pirtobrutinib
Participants received either 150 mg of idelalisib administered twice-daily (BID) orally on Days 1 through 28 of a 28-day cycle in combination with 375 milligram per square meter (mg/m\^2) of rituximab by intravenous (IV) infusion on day 1 of cycle 1, then 4 IV infusions of rituximab 500 mg/m\^2 every 2 weeks (Q2W) and 3 IV infusions of rituximab 500 mg/m\^2 every 4 weeks (Q4W) or 70 mg/m\^2 of bendamustine administered IV on day 1 and 2 of each 28-day cycle from cycles 1 to 6 in combination with 375 mg/m\^2 of rituximab IV on day 1 of cycle 1, then 500 mg/m\^2 of rituximab on day 1 of each 28-day cycle from cycles 2 to 6.
Drug: Idelalisib · Drug: Bendamustine · Drug: Rituximab
Oral Pirtobrutinib
Also known as: LOXO-305, LY3527727
Oral
Also known as: Zydelig
IV
Also known as: Treanda, Treakisym, Ribomustin, Levact
IV
Also known as: Rituxan, MabThera, Truxima
Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)
PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an IRC according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018.
Time frame: Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)
PFS Assessed by Investigator
PFS is defined as time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an investigator according to iwCLL 2018.
Time frame: Randomization to Disease Progression or Death Due to Any Cause (Up to 36 Months)
Overall Survival (OS)
OS was defined as time from randomization to death due to any cause.
Time frame: Randomization to Death from Any Cause (Up to 36 months)
Time to Next Treatment (TTNT)
TTNT was defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), therapy of pirtobrutinib for Arm B patients, or death due to any cause, whichever occurs first.
Time frame: Randomization to Subsequent Anticancer Therapy, Therapy of Pirtobrutinib or Death Due to Any Cause (Up to 36 Months)
Event Free Survival (EFS)
EFS is defined as the time from randomization to the first occurrence of: * Documented disease progression per iwCLL 2018 criteria as assessed by Investigator; or * Initiation of subsequent anticancer therapy for CLL/SLL; or * Unacceptable toxicity leading to treatment discontinuation as assessed by the Investigator; or * Death (due to any cause).
Time frame: Randomization to Disease Progression, Subsequent Anticancer Therapy, Unacceptable Toxicity Leading to Treatment Discontinuation, or Death Due to Any Cause (Up to 36 Months)
Percentage of Participants With Overall Response Rate (ORR) Assessed by Investigator
ORR according to investigator-assessed best overall response (BOR) based on iwCLL 2018 is defined as the number of participants who achieve a BOR of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) at or before the initiation of subsequent anticancer therapy divided by the total number of participants randomized to each treatment arm.
Time frame: Randomization to Subsequent Anticancer Therapy, Disease Progression or Death Due to Any Cause (Up to 36 Months)
Time to Worsening (TTW) of CLL/SLL Related Symptoms
TTW was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms. The time to sustained patient-reported outcome (PRO) deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A \& Arm B - Idelalisib plus Rituximab) and up to Week 21 + Safety follow-up of up to 5 weeks (Arm B - Bendamustine plus Rituximab) assessment time point prior to disease progression.
Time frame: Baseline up to Week 25 (Arm A and Arm B - Idelalisib plus Rituximab) & Baseline up to Week 21 + Safety Follow-Up of up to 5 Weeks (Arm B - Bendamustine plus Rituximab)
Time to Worsening (TTW) of Physical Function
Time of worsening was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms. The time to sustained PRO deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A and IdelaR) and up to Week 21 + Safety follow-up (BR) assessment time point prior to disease progression.
Time frame: Baseline up to Week 25 (Arm A and Arm B - Idelalisib plus Rituximab) & Baseline up to Week 21 + Safety Follow-Up of up to 5 Weeks (Arm B - Bendamustine plus Rituximab)
| Milestone | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| Started | 119 | 119 |
| Received at least 1 dose of study drug | 116 | 109 |
| Completed | 0 | 0 |
| Not completed | 119 | 119 |
| Withdrew: Progressive disease | 2 | 0 |
| Withdrew: Death | 38 | 32 |
| Withdrew: Withdrawal by subject | 10 | 19 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: On study treatment | 46 | 5 |
| Withdrew: Off treatment on post-treatment-discontinuation follow-up | 23 | 61 |
PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an IRC according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018.
| Months | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) | 13.96 (11.24 to 16.56) | 8.74 (8.08 to 10.38) |
PFS is defined as time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an investigator according to iwCLL 2018.
| Months | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| PFS Assessed by Investigator | 15.28 (12.81 to 19.94) | 9.20 (7.33 to 10.64) |
OS was defined as time from randomization to death due to any cause.
| Months | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| Overall Survival (OS) | 29.67 (27.10 to NA) | NA (28.88 to NA) |
TTNT was defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), therapy of pirtobrutinib for Arm B patients, or death due to any cause, whichever occurs first.
| Months | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| Time to Next Treatment (TTNT) | 23.95 (17.84 to 29.67) | 10.91 (8.74 to 12.48) |
EFS is defined as the time from randomization to the first occurrence of: * Documented disease progression per iwCLL 2018 criteria as assessed by Investigator; or * Initiation of subsequent anticancer therapy for CLL/SLL; or * Unacceptable toxicity leading to treatment discontinuation as assessed by the Investigator; or * Death (due to any cause).
| Months | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| Event Free Survival (EFS) | 14.06 (11.40 to 16.95) | 7.62 (4.80 to 8.80) |
ORR according to investigator-assessed best overall response (BOR) based on iwCLL 2018 is defined as the number of participants who achieve a BOR of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) at or before the initiation of subsequent anticancer therapy divided by the total number of participants randomized to each treatment arm.
| percentage of participants | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| Percentage of Participants With Overall Response Rate (ORR) Assessed by Investigator | 66.4 (57.15 to 74.78) | 48.7 (39.47 to 58.07) |
TTW was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms. The time to sustained patient-reported outcome (PRO) deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A \& Arm B - Idelalisib plus Rituximab) and up to Week 21 + Safety follow-up of up to 5 weeks (Arm B - Bendamustine plus Rituximab) assessment time point prior to disease progression.
| Months | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| Time to Worsening (TTW) of CLL/SLL Related Symptoms | NA (NA to NA) | NA (5.7 to NA) |
Time of worsening was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms. The time to sustained PRO deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A and IdelaR) and up to Week 21 + Safety follow-up (BR) assessment time point prior to disease progression.
| Months | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| Time to Worsening (TTW) of Physical Function | NA (NA to NA) | NA (5.7 to NA) |
Collected over Baseline up to data cut-off date 29-August-2024 (up to 36 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A - Pirtobrutinib | 38/119 (31.9%) | 60/116 (51.7%) | 94/116 (81%) |
| Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab | 32/119 (26.9%) | 53/109 (48.6%) | 103/109 (94.5%) |
| Event | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| PneumoniaInfections and infestations | 20/116 | 12/109 |
| Covid-19Infections and infestations | 2/116 | 6/109 |
| Covid-19 pneumoniaInfections and infestations | 5/116 | 4/109 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/116 | 4/109 |
| DiarrhoeaGastrointestinal disorders | 0/116 | 4/109 |
| PyrexiaGeneral disorders | 2/116 | 4/109 |
| Vulval abscessInfections and infestations | 0/116 | 1/32 |
| Vaginal haemorrhageReproductive system and breast disorders | 1/34 | 0/109 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/116 | 3/109 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/116 | 3/109 |
| Event | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 20/116 | 30/109 |
| PyrexiaGeneral disorders | 14/116 | 28/109 |
| FatigueGeneral disorders | 16/116 | 27/109 |
| NauseaGastrointestinal disorders | 13/116 | 23/109 |
| AnaemiaBlood and lymphatic system disorders | 21/116 | 21/109 |
| CoughRespiratory, thoracic and mediastinal disorders | 20/116 | 20/109 |
| NeutropeniaBlood and lymphatic system disorders | 21/116 | 17/109 |
| Neutrophil count decreasedInvestigations | 9/116 | 19/109 |
| VomitingGastrointestinal disorders | 7/116 | 18/109 |
| Covid-19Infections and infestations | 14/116 | 18/109 |
All randomized participants
| Age, Continuous(years) | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| Mean | 66.90 ± 9.32 | 67.00 ± 8.52 | 67.00 ± 8.91 |
| Sex: Female, Male(Participants) | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| Female | 36 | 36 | 72 |
| Male | 83 | 83 | 166 |
| Ethnicity (NIH/OMB)(Participants) | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 10 |
| Not Hispanic or Latino | 107 | 108 | 215 |
| Unknown or Not Reported | 6 | 7 | 13 |
| Race (NIH/OMB)(Participants) | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 14 | 15 | 29 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 5 | 6 |
| White | 98 | 95 | 193 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 4 | 10 |
| Region of Enrollment(participants) | Arm A - Pirtobrutinib | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab | Total |
|---|---|---|---|
| Australia | 5 | 2 | 7 |
| Austria | 1 | 1 | 2 |
| Belgium | 1 | 0 | 1 |
| Canada | 4 | 6 | 10 |
| China | 10 | 14 | 24 |
| Croatia | 0 | 1 | 1 |
| Czechia | 2 | 1 | 3 |
| France | 5 | 4 | 9 |
| Germany | 2 | 4 | 6 |
| Hungary | 3 | 4 | 7 |
| Ireland | 2 | 1 | 3 |
| Israel | 2 | 0 | 2 |
| Italy | 23 | 19 | 42 |
| Japan | 3 | 0 | 3 |
| Poland | 14 | 17 | 31 |
| Russia | 0 | 1 | 1 |
| South Korea | 1 | 0 | 1 |
| Spain | 4 | 2 | 6 |
| Switzerland | 2 | 1 | 3 |
| Taiwan | 0 | 1 | 1 |
| Turkey | 1 | 1 | 2 |
| United Kingdom | 14 | 6 | 20 |
| United States | 20 | 33 | 53 |
Showing the first 100 of 232 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Aug 2023, 29 months.
Results were first posted in Mar 2025, 1 year 6 months after primary completion. A results delay was requested in Aug 2024.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 29 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →